Dr. Aaron Rossi’s vision of a full-service laboratory in Pekin, Ill., is taking form one test at a time.
Dr. Rossi opened Reditus Laboratories as a histology lab for podiatrists in June 2019. The lab had 10 employees, today, Reditus has just under 300 employees and has evolved into a full-service lab that includes molecular testing, clinical laboratory testing (hematology and chemistry) and cytogenetics (bladder cancer testing using UroVysion), while continuing to provide histology services.
Reditus plans to expand testing capabilities into areas of microbiology, next generation sequencing and expanded cancer testing by flow-cytometry and sequencing methods. Our new lab is 23,000 square feet designed to accomodate more staff and testing equipment.
To quickly and accurately diagnose soft tissue and wound infections, Reditus acquired its first real-time reverse transcriptase polymerase chain reaction (RT-PCR) machine in February 2020. Meanwhile, SARS-CoV-2 (COVID-19) had entered Illinois. Since April 2020, Reditus has performed more than 2.7 million tests for COVID-19.
Even with the staggering numbers, Reditus remains focused on quality. Reditus is accredited by the College of American Pathologists (CAPs). The CAP Laboratory Accreditation Program is a rigorous accreditation process certifying that Reditus meets standards in areas such as laboratory safety, procedures, training, documentation, and personnel qualifications. Reditus met all the standards with a perfect score.
As COVID-19 testing continues, Reditus has expanded into sequencing of randomly selected positive COVID-19 samples to identify variants, which are more contagious and may have potential resistance to the vaccines. Reditus shares this data with Illinois Department of Public Health, the U.S. Centers for Disease Control and Prevention and GISAID, a global initiative that provides access to genomic data of influenza viruses and COVID-19.
Reditus also is expanding into offering a FluV19 At-Home Collection Kit, in which customers will be able to collect their own nasal specimen from the comfort of their home and overnight the sample to Reditus. Reditus will test the sample for Influenza A and B as well as COVID-19. Results will be available to the customer 24 to 48 hours after the lab receives the specimens.
“I am proud of our growth and gratified that we have been able to develop a full-service lab in Central Illinois,” Dr. Rossi said. “But it’s not about the numbers. My goal when opening Reditus Laboratories was to become one of the nation’s top clinical diagnostic laboratories. We have been able to accomplish this, even during a pandemic, which speaks volumes to the quality and dedication of our staff, who ensure that the patient always comes first.”